SorooX Details Strategy After Acquiring CHA Vaccine Institute: "Building Dual Growth Structure in Lighting and Bio"

SOROOX has outlined a concrete business strategy following its acquisition of CHA Vaccine Institute, presenting a growth roadmap centered on lighting and bio sectors.

On March 23, the company explained that securing management rights of CHA Vaccine Institute was not merely a share purchase, but a strategic decision aimed at maintaining and strengthening the competitiveness of its existing lighting business, while also securing new growth engines through collaboration with ARIBIO.

SOROOX plans to maintain a stable performance base through its existing lighting business, while expanding its mid- to long-term growth foundation in the bio sector by establishing a structure centered on CHA Vaccine Institute and ARIBIO. The company emphasized that its core strategy is a portfolio approach that ensures both stability and growth potential.

The roles of affiliates are also expected to become clearer. ARIBIO will focus on clinical trials and commercialization of the oral Alzheimer’s treatment AR1001. CHA Vaccine Institute will strengthen its R&D capabilities and expand its pipeline, focusing on vaccines, immune technologies, and natural killer (NK) cell-based businesses. SOROOX will serve as the foundational link connecting these businesses, aiming to build a structure in which both lighting and bio sectors can grow simultaneously.

The company also highlighted that this structure reduces dependency on any single business or individual pipeline, thereby creating a diversified growth base. It is expected that the combination of CHA Vaccine Institute’s R&D and commercialization capabilities, ARIBIO’s clinical development drive, and SOROOX’s established business foundation will further clarify the group-wide growth strategy.

Additionally, the company interpreted CHA Bio’s continued position as the second-largest shareholder after the transaction as a reflection of expectations for future business development and corporate value, rather than merely a change in governance structure.

A SOROOX representative stated, “This acquisition is a process of adding a new growth axis on top of our existing business foundation,” adding, “We will further advance the lighting business and gradually concretize the growth structure that connects CHA Vaccine Institute and ARIBIO.” The representative continued, “We will ensure that our ongoing strategies and execution capabilities are demonstrated in the market through tangible results.”

This content was produced with the assistance of AI translation services.